

Resource Summary Report

Generated by [NIF](#) on Aug 8, 2026

Crl:NU(NCr)-Foxn1^{nu}

RRID:IMSR_CRL:490

Type: Organism

Proper Citation

RRID:IMSR_CRL:490

Organism Information

URL: <http://www.criver.com/products-services/basic-research/find-a-model/athymic-nude-mouse>

Proper Citation: RRID:IMSR_CRL:490

Description: Mus musculus with name Crl:NU(NCr)-Foxn1^{nu} from IMSR.

Species: Mus musculus

Notes: gene symbol note: ; outbred stock:

Catalog Number: CRL:490

Database: Charles River Laboratories

Database Abbreviation: CRL

Availability: live

Organism Name: Crl:NU(NCr)-Foxn1^{nu}

Record Creation Time: 20250513T062410+0000

Record Last Update: 20260808T055927+0000

Ratings and Alerts

No rating or validation information has been found for Crl:NU(NCr)-Foxn1^{nu}.

No alerts have been found for Crl:NU(NCr)-Foxn1^{nu}.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: Charles River Laboratories

Usage and Citation Metrics

We found 11630 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Pougoue Ketchemen J, et al. (2026) Potency and safety of novel [225Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer. British journal of cancer, 134(12), 1820.

Vaubel RA, et al. (2026) Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts. Neuro-oncology advances, 8(1), vda259.

Tikum AF, et al. (2026) [225Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer. Breast cancer research : BCR, 28(1), 44.

Lan L, et al. (2026) A Jagged1-regulated hybrid-EMT state identifies pancreatic cancer stem cells. Cell reports, 45(2), 116909.

Liang X, et al. (2026) Colorectal cancer-derived osteopontin rewires macrophages into a pro-metastatic M2 state via the PI3K/AKT/CSF1-CSF1R axis. Cell death discovery, 12(1), 92.

Halbers LP, et al. (2026) Expanded applications of bioluminescence microscopy with phasor analysis. Cell reports methods, 6(4), 101344.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. Cell, 189(10), 2898.

Young RG, et al. (2026) ACS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis. Cancer research, 86(14), 3502.

Tsuji T, et al. (2026) Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells. Cancer research, 86(6), 1414.

Liu X, et al. (2026) Prenatal bisphenol A exposure reprograms SF1-lactylation pathways to promote endometriosis susceptibility. iScience, 29(5), 115608.

Solernó LM, et al. (2026) Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma. Frontiers in medicine, 13, 1864843.

Zhu GN, et al. (2026) DNA hypomethylation-activated PRAME drives early-stage lung adenocarcinoma recurrence via ZNF740 and PI3K/AKT/mTOR signaling. Translational lung cancer research, 15(4), 72.

Wu N, et al. (2026) Arginine deprivation enhances ASS1-negative glioblastoma radiosensitivity via epigenetic silencing of DNA repair genes. *Cell death & disease*.

Guo X, et al. (2026) The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads. *iScience*, 29(7), 116390.

Li H, et al. (2026) Novel NOTCH2-NTRK1 fusion confers osimertinib resistance in EGFR-mutant non-small cell lung cancer by interacting with EGFR. *Translational oncology*, 63, 102577.

Echigo H, et al. (2026) Combination therapy of an ²¹¹At-labeled RGD peptide and immune checkpoint blockade to enhance antitumor efficacy. *European journal of nuclear medicine and molecular imaging*, 53(2), 992.

Liang BG, et al. (2026) The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC. *Hepatology (Baltimore, Md.)*, 83(4), 771.

Xiao Q, et al. (2026) GLIS3 drives epithelial-mesenchymal transition and cancer stem-like traits in stomach adenocarcinoma via TGFBR3-Hedgehog signaling. *Frontiers in oncology*, 16, 1826297.

Xiao W, et al. (2026) Synergistic effect of Pladienolide B and cisplatin: enhancing autophagy in hepatoma cells through the AMPK/mTOR/ULK1 pathway. *Cell death discovery*, 12(1).

Cao Y, et al. (2026) CTSZ-dependent anoikis resistance enhances malignant characters of glioblastoma via NF- κ B signaling. *iScience*, 29(6), 115992.